One point to remember, Amarin can put out there own generic before the generic companies do, and just charge less, Ive seen it done many times in the pharmacy over the years
Warner-Lambert had a lot of overhead that came along with it's product line-up. Who knows what the costs were to integrate Warner's assets. Amarin is as lean as you can get for a Public company. The potential suiter can hit the ground running and earn revenue day one. IMO, the valuation calculations for Amarin, by comparison, should be substantially straight forward.
News 
Market Data 
Discover 
